Physician profile
Rupal B Bhingradia
NPI 1033461231
$13,100.07
in general payments reported to CMS, 2019-2025
10 companies · $13K in 2025
The $13K reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $184 · 2021: $204 · 2022: $46.25 · 2023: $83.80 · 2024: $70.73 · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $12K · Food and Beverage: $185.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $12,480.67 |
| Food and Beverage | $185.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $12,480.67 | 2025 | |
| Glaxosmithkline, LLC. | $291.72 | 2019-2021 | |
| Pfizer INC. | $134.54 | 2023-2024 | |
| Gilead Sciences, INC. | $58.19 | 2019-2021 | |
| Modernatx, INC. | $30.72 | 2025 | |
| Genentech USA, INC. | $29.24 | 2019-2022 | |
| Amarin Pharma, INC. | $24.55 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $19.99 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $16.57 | 2022 | |
| Horizon Therapeutics Plc | $13.88 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rupal Bhingradia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.